Abstract
Farnesyl-diphosphate farnesyltransferase 1 (FDFT1, squalene synthase), a membrane-associated enzyme, synthesizes squalene via condensation of two molecules of farnesyl pyrophosphate. Accumulating evidence has noted that FDFT1 plays a critical role in cancer, particularly in metabolic reprogramming, cell proliferation, and invasion. Based on these advances in our knowledge, FDFT1 could be a potential target for cancer treatment. This review focuses on the contribution of FDFT1 to the hallmarks of cancer, and further, we discuss the applicability of FDFT1 as a cancer prognostic marker and target for anticancer therapy.
Keywords:
cholesterol synthesis; farnesyl-diphosphate farnesyltransferase 1; lipid rafts; prognostic marker; tumour progression.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Animals
-
Antineoplastic Agents / chemistry
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Agents / therapeutic use
-
Cholesterol / metabolism
-
Disease Susceptibility*
-
Drug Evaluation, Preclinical
-
Enzyme Inhibitors / chemistry
-
Enzyme Inhibitors / pharmacology
-
Enzyme Inhibitors / therapeutic use
-
Farnesyl-Diphosphate Farnesyltransferase / antagonists & inhibitors
-
Farnesyl-Diphosphate Farnesyltransferase / genetics*
-
Farnesyl-Diphosphate Farnesyltransferase / metabolism
-
Humans
-
Neoplasms / drug therapy
-
Neoplasms / etiology*
-
Neoplasms / metabolism*
-
Neoplasms / pathology
-
Structure-Activity Relationship
-
Tumor Microenvironment* / drug effects
-
Tumor Microenvironment* / genetics
Substances
-
Antineoplastic Agents
-
Enzyme Inhibitors
-
Cholesterol
-
Farnesyl-Diphosphate Farnesyltransferase